{"url_path":"/sec/aura/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-11","source_url":"https://www.sec.gov/Archives/edgar/data/1501796/0001193125-26-216808-index.html","accession_number":"0001193125-26-216808","cik":"0001501796","ticker":"AURA","issuer_name":"Aura Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1501796/0001193125-26-216808-index.html","primary_entity_key":"0001501796","primary_entity_name":"Aura Biosciences, Inc."},"word_count":491,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n \n\nExhibit\n\nNumber\n\nDescription\n\n3.1\n\n \n\n[Tenth Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect, as amended by the Certificate of Amendment, dated June 20, 2024 (incorporated by reference to Exhibit 3.1 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40971) filed on August 8, 2024).](https://www.sec.gov/Archives/edgar/data/1501796/000095017024093308/aura-ex3_1.htm)\n\n3.2\n\n \n\n[Amended and Restated Bylaws of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.2 of the Registrant’s Annual Report on Form 10-K (File No. 001-40971) filed on March 23, 2022).](https://www.sec.gov/Archives/edgar/data/1501796/000095017022004425/aura-ex3_2.htm)\n\n4.1\n\n \n\n[Fifth Amended and Restated Investors’ Rights Agreement (incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-260156) filed on October 8, 2021)](https://www.sec.gov/Archives/edgar/data/1501796/000119312521295543/d209588dex42.htm).\n\n10.1%\n\n \n\n[Second Amendment to License Agreement with Clearside Biomedical, Inc., dated March 25, 2026.](aura-ex10_1.htm)\n\n31.1*\n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](aura-ex31_1.htm)\n\n31.2*\n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](aura-ex31_2.htm)\n\n32.1#\n\n[Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](aura-ex32_1.htm)\n\n101.INS\n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.\n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents.\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n* Filed herewith.\n\n# These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.\n\n% Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because they are both (i) not material and (ii) the type that the Registrant treats as private or confidential. A copy of the omitted portions will be furnished to the SEC upon its request.\n\n \n\n78\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\nAura Biosciences, Inc.\n\nDate: May 11, 2026\n\nBy:\n\n/s/ Natalie Holles\n\nNatalie Holles\n\nChief Executive Officer and President\n\n \n\n \n\n \n\n(Principal Executive Officer)\n\n \n\n \n\n \n\n \n\nDate: May 11, 2026\n\n \n\nBy:\n\n/s/ Anthony Gibney\n\n \n\n \n\n \n\nAnthony Gibney\n\n \n\n \n\n \n\nChief Financial and Business Officer\n\n \n\n \n\n \n\n(Principal Financial Officer)\n\n \n\nDate: May 11, 2026\n\nBy:\n\n/s/ Amy Elazzouzi\n\n \n\n \n\n \n\nAmy Elazzouzi\n\n \n\n \n\n \n\nSenior Vice President, Finance\n\n \n\n \n\n \n\n(Principal Accounting Officer)\n\n \n\n79"}